Nature cancer
Axicabtagene ciloleucel in combination with rituximab for refractory large B cell lymphoma: the phase 2, single-arm ZUMA-14 trial.
Paolo Strati, Lori Leslie, Parveen Shiraz, Lihua E Budde, Olalekan O Oluwole, Matthew Ulrickson, Aravind Ramakrishnan, Teresa Zhang, Jennifer Sun, Francesca Milletti, Justyna Kanska, Rhine Shen, Frank Neumann, Hairong Xu, Krish Patel
Published: 202610.1038/s43018-025-01102-1
Abstract
CD19-negative relapse occurs in ~30% of persons with relapsed or refractory large B cell lymphoma (LBCL) who respond to axicabtagene ciloleucel (axi-cel; CD19-directed chimeric antigen receptor (CAR) T cell therapy). In this phase 2 single-arm study,…
Preview only. Read the full abstract at the source